[Prolonged weaning after long-term ventilation due to SARS-CoV-2 infection: a multicenter retrospective analysis].

IF 1.2 Q4 RESPIRATORY SYSTEM Pneumologie Pub Date : 2024-08-15 DOI:10.1055/a-2370-1763
Florian Geismann, Lucas Braunschmidt, Arno Mohr, Thorsten Hardebusch, Michael Westhoff, Michael Dreher, Tobias Müller, Alexander Heine, Hemendra Ramdatt, Anne Obst, Ralf Ewert
{"title":"[Prolonged weaning after long-term ventilation due to SARS-CoV-2 infection: a multicenter retrospective analysis].","authors":"Florian Geismann, Lucas Braunschmidt, Arno Mohr, Thorsten Hardebusch, Michael Westhoff, Michael Dreher, Tobias Müller, Alexander Heine, Hemendra Ramdatt, Anne Obst, Ralf Ewert","doi":"10.1055/a-2370-1763","DOIUrl":null,"url":null,"abstract":"<p><p>Some of the patients with SARS-CoV-2 infection (COVID-19) received invasive ventilation during inpatient care. Weaning from ventilation was difficult for some patients (so-called prolonged weaning).</p><p><strong>Patients: </strong>Patients (n=751) with prolonged weaning (reason for ventilation \"pneumonia\" and \"acute respiratory failure\") from four centers for the period 2011-23 from the \"WeanNet\" registry were used as a matched group.</p><p><strong>Results: </strong>The median duration of intensive medical care was 39 (25-68) days. In 19% (37/193) of patients, ECMO support was necessary for a median of 27 (18-51) days. In-hospital mortality was 8.3% (2.7% with vs. 9.6% without ECMO) and 6.8% died in the comparison group. At discharge, 84% (vs. 77% in the control group) were completely weaned and 2.6% (vs. 17.6% in the control group) of patients received non-invasive treatment. Invasive ventilation was still necessary in 7.8% (control group 15.7%). In the observation period of 6 months after discharge, 22.4% of patients required inpatient care and a further 14.1% after 12 months. The overall mortality at 12-month follow-up was 20,6% (5.6% with vs. 24.6% without ECMO).</p><p><strong>Discussion: </strong>The mortality rate of ventilated patients with COVID-19 was very low at 8.3% in the four weaning centers studied. The mortality rate of patients with ECMO treatment was only 2.7%. The mortality rate in the control group was 7.3%. The lower mortality of patients with ECMO treatment was also evident at follow-up of up to 12 months.Patients with prolonged weaning who received invasive ventilation due to COVID-19 showed comparable results in terms of successful weaning and mortality compared to a control group from the WeanNet registry. The long-term results with a survival of more than 80% for the first year after discharge were encouraging.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2370-1763","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Some of the patients with SARS-CoV-2 infection (COVID-19) received invasive ventilation during inpatient care. Weaning from ventilation was difficult for some patients (so-called prolonged weaning).

Patients: Patients (n=751) with prolonged weaning (reason for ventilation "pneumonia" and "acute respiratory failure") from four centers for the period 2011-23 from the "WeanNet" registry were used as a matched group.

Results: The median duration of intensive medical care was 39 (25-68) days. In 19% (37/193) of patients, ECMO support was necessary for a median of 27 (18-51) days. In-hospital mortality was 8.3% (2.7% with vs. 9.6% without ECMO) and 6.8% died in the comparison group. At discharge, 84% (vs. 77% in the control group) were completely weaned and 2.6% (vs. 17.6% in the control group) of patients received non-invasive treatment. Invasive ventilation was still necessary in 7.8% (control group 15.7%). In the observation period of 6 months after discharge, 22.4% of patients required inpatient care and a further 14.1% after 12 months. The overall mortality at 12-month follow-up was 20,6% (5.6% with vs. 24.6% without ECMO).

Discussion: The mortality rate of ventilated patients with COVID-19 was very low at 8.3% in the four weaning centers studied. The mortality rate of patients with ECMO treatment was only 2.7%. The mortality rate in the control group was 7.3%. The lower mortality of patients with ECMO treatment was also evident at follow-up of up to 12 months.Patients with prolonged weaning who received invasive ventilation due to COVID-19 showed comparable results in terms of successful weaning and mortality compared to a control group from the WeanNet registry. The long-term results with a survival of more than 80% for the first year after discharge were encouraging.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[SARS-CoV-2感染导致长期通气后延长断奶时间:一项多中心回顾性分析]。
部分 SARS-CoV-2 感染者(COVID-19)在住院治疗期间接受了有创通气。一些患者很难从通气中断奶(即所谓的长时间断奶):以 "WeanNet "登记册中 2011-23 年间四个中心的延长断气患者(n=751)(通气原因为 "肺炎 "和 "急性呼吸衰竭")为配对组:重症监护的中位持续时间为 39 (25-68) 天。19%(37/193)的患者需要接受 ECMO 支持,中位时间为 27(18-51)天。院内死亡率为 8.3%(使用 ECMO 的为 2.7%,未使用 ECMO 的为 9.6%),对比组的死亡率为 6.8%。出院时,84% 的患者(对照组为 77%)已完全断奶,2.6% 的患者(对照组为 17.6%)接受了无创治疗。仍有 7.8%(对照组为 15.7%)的患者需要进行侵入性通气。在出院后 6 个月的观察期内,22.4% 的患者需要住院治疗,12 个月后又有 14.1%的患者需要住院治疗。在 12 个月的随访中,总死亡率为 20.6%(使用 ECMO 的 5.6%,未使用 ECMO 的 24.6%):讨论:在所研究的四个断奶中心中,COVID-19 通气患者的死亡率非常低,仅为 8.3%。接受 ECMO 治疗的患者死亡率仅为 2.7%。对照组的死亡率为 7.3%。在长达 12 个月的随访中,接受 ECMO 治疗的患者死亡率较低的情况也很明显。与 WeanNet 登记的对照组相比,因 COVID-19 而接受有创通气的长期断奶患者在成功断奶和死亡率方面的结果相当。长期结果令人鼓舞,出院后第一年的存活率超过 80%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pneumologie
Pneumologie RESPIRATORY SYSTEM-
CiteScore
1.80
自引率
16.70%
发文量
416
期刊介绍: Organ der Deutschen Gesellschaft für Pneumologie DGP Organ des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose DZK Organ des Bundesverbandes der Pneumologen BdP Fachärzte für Lungen- und Bronchialheilkunde, Pneumologen und Allergologen
期刊最新文献
[Current status of lung cancer care in Germany in the context of treatment centralization and lack of personnel]. [Role of red blood cell (RBC) transfusions in patients with prolonged mechanical ventilation during weaning process]. [Critical Closing Pressure (Pcrit) and Negative (Subatmospheric) Expiratory Pressure (NEP) for Diagnosis of Pharyngeal Collapsibility in Patients With Obstructive Sleep Apnea (OSA)]. Dexamethasone, Remdesivir and Azithromycin modulate ACE2 and IL-6 in Lung Epithelial Cells. [Diagnosis and Treatment of Hypersensitivity Pneumonitis - S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1